Breast Cancer Clinical Trial
Official title:
A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors
| Verified date | March 2024 |
| Source | Washington University School of Medicine |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The scientific premise for this study is the known impact of overweight/obesity on breast cancer risk and outcomes, the association between advanced glycation end-products (AGE) and high fat, highly processed foods common in Western diets, and the preclinical evidence suggesting a link between AGE and breast cancer independent of weight. The association between dietary and serum AGE in breast cancer survivors and prognosis has not been previously evaluated. However, preclinical studies suggest that AGE may represent a novel, lifestyle-linked, modifiable, prognostic biomarker, which could be targeted through lifestyle (diet and exercise) and/or pharmaceutical interventions to improve breast cancer prognosis. The proposed study will pave the way for a large scale randomized controlled trial to evaluate the impact of a low AGE diet on weight (BMI), known (IL-6 and CRP) and novel (AGE and RAGE) prognostic biomarkers, and ultimately on breast cancer prognosis.
| Status | Completed |
| Enrollment | 14 |
| Est. completion date | March 22, 2024 |
| Est. primary completion date | March 22, 2024 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Diagnosis of breast cancer, any subtype, stage I-III, within the last 36 months, who have completed primary therapy of their breast cancer (surgery, radiation, and chemotherapy). Must be at least 4 weeks post their last chemotherapy or radiation therapy. Concurrent hormonal therapy is allowed. - At least 18 years of age. - Determined to have a high AGE diet at baseline (dietary AGE intake greater than 14 Eq/day as assessed by food frequency questionnaire). - Ability to understand and willingness to sign an IRB approved written informed consent document. Exclusion Criteria: - Diagnosis of diabetes. - History of eating disorder or body dysmorphic disorder. - Active tobacco use (tobacco is a source of advanced glycation end products). - Active participation in other dietary or physical activity clinical trials or community interventions. - Taking and unwilling/unable to stop taking B-6 (pyridoxamine), B1 (thiamine) or metformin (all known AGE inhibitors). |
| Country | Name | City | State |
|---|---|---|---|
| United States | Washington University School of Medicine | Saint Louis | Missouri |
| Lead Sponsor | Collaborator |
|---|---|
| Washington University School of Medicine | American Cancer Society, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Feasibility as measured by adherence rate | Feasibility is a defined adherence rate of at least 80% of participants enrolled
Diet adherence will be categorized by the study dietitian at the end of the study and before the results of AGEs in serum or any analysis of outcomes to avoid bias. Following each phone session with the participants, the dietitian will elicit answers to the following question: since the last call did the participant use any cooking methods they were advised to avoid for certain food items? (yes/no). The information will be used to calculate an adherence score. Adherence score is % phone calls of patient's report for full maintaining instructions to reduce AGEs. Very high adherence= =80%; good adherence= 60-80%; partial adherence= 40-60%; lack of adherence but intention to adhere more in the future= =40%; lack of adherence and no intention to adhere more= =40% |
At study completion for all enrolled participants (estimated to be 15 months) | |
| Primary | Feasibility as measured by dropout rate | -Feasibility is defined as a dropout rate of less than 20% of participants enrolled | At study completion for all enrolled participants (estimated to be 15 months) | |
| Secondary | Change in dietary AGE | -Dietary AGE is estimated based on analysis of the 3 day food record patients will complete at baseline and study completion. A specific dietary AGE value will be assigned to each item on the 3 day food recall by consultant and dietary AGE expert Jaime Uribarri, MD. This value is based on his published dietary AGE database which accounts for type of food, portion size and cooking methods. | At baseline and study completion (24 weeks) | |
| Secondary | Change in serum AGE | Blood specimens for serum AGE analysis will be shipped from the University of San Diego Biorepository to the Medical University of South Carolina to be analyzed in the lab of study team member and expert AGE analyst, Dr. David Turner.
AGE (measured by the AGE metabolite carboxymethyllysine (ug/ml)) will be assessed in serum using commercially available 96-well format ELISA's and ROS detection kits (Cell Biolabs). Ne-carboxymethyllysine (CML) is an AGE metabolite extensively studied in animal models of disease and with regard to food content. |
Baseline, week 12, and week 24 | |
| Secondary | Correlation between serum AGE levels and BMI | -The relationship between serum AGE levels and BMI will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between serum AGE levels and serum CRP | -The relationship between serum AGE levels and serum CRP will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between serum AGE levels and IL6 | -The relationship between serum AGE levels and IL6 will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between serum AGE levels and glucose | -The relationship between serum AGE levels and glucose will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between serum AGE levels and leptin | -The relationship between serum AGE levels and leptin will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between serum AGE levels and adiponectin | -The relationship between serum AGE levels and adiponectin will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between dietary AGE and BMI | -The relationship between dietary AGE and BMI will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between dietary AGE and serum CRP | -The relationship between dietary AGE and serum CRP will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between dietary AGE and IL6 | -The relationship between dietary AGE and IL6 will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between dietary AGE and insulin | -The relationship between dietary AGE and insulin will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between dietary AGE and glucose | -The relationship between dietary AGE and glucose will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between dietary AGE and leptin | -The relationship between dietary AGE and leptin will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks | |
| Secondary | Correlation between dietary AGE and adiponectin | -The relationship between dietary AGE and adiponectin will be assessed using rank based correlation. | Baseline, 12 weeks, and 24 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |